1. Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. Issue 1 (4th June 2018) Authors: Li, Yiwen; Carpenito, Carmine; Wang, George; Surguladze, David; Forest, Amelie; Malabunga, Maria; Murphy, Mary; Zhang, Yiwei; Sonyi, Andreas; Chin, Darin; Burtrum, Douglas; Inigo, Ivan; Pennello, Anthony; Shen, Leyi; Malherbe, Laurent; Chen, Xinlei; Hall, Gerald; Haidar, Jaafar N.; Ludwig, Dale L... Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. Issue 1 (30th April 2018) Authors: Li, Yiwen; Carpenito, Carmine; Wang, George; Surguladze, David; Forest, Amelie; Malabunga, Maria; Murphy, Mary; Zhang, Yiwei; Sonyi, Andreas; Chin, Darin; Burtrum, Douglas; Inigo, Ivan; Pennello, Anthony; Shen, Leyi; Malherbe, Laurent; Chen, Xinlei; Hall, Gerald; Haidar, Jaafar N.; Ludwig, Dale L... Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Issue 1 (4th June 2018) Authors: Holmgaard, Rikke B.; Schaer, David A.; Li, Yanxia; Castaneda, Stephen P.; Murphy, Mary Y.; Xu, Xiaohong; Inigo, Ivan; Dobkin, Julie; Manro, Jason R.; Iversen, Philip W.; Surguladze, David; Hall, Gerald E.; Novosiadly, Ruslan D.; Benhadji, Karim A.; Plowman, Gregory D.; Kalos, Michael; Driscoll, K... Journal: Journal for immunotherapy of cancer Issue: Volume 6:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. (4th November 2015) Authors: Schaer, David; Li, Yanxia; Castaneda, Stephen; Inigo, Ivan; Surguladze, David; Xu, Xiaohong; Nugent, Desiree; Murphy, Mary; Hall, Gerald; Benhadji, Karim; Guba, Susan; Li, Yiwen; Kalos, Michael; Driscoll, Kyla Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Issue 2 (December 2015) Authors: Schaer, David; Li, Yanxia; Castaneda, Stephen; Inigo, Ivan; Surguladze, David; Xu, Xiaohong; Nugent, Desiree; Murphy, Mary; Hall, Gerald; Benhadji, Karim; Guba, Susan; Li, Yiwen; Kalos, Michael; Driscoll, Kyla Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗